Rifaximin and lactulose are widely used in patients with hepatic encephalopathy. Limited data exists on the comparative outcomes regarding spontaneous bacterial peritonitis (SBP), renal adverse events and ER visits in patients with cirrhosis on rifaximin versus lactulose-based therapy…